论文部分内容阅读
心力衰竭(heart failure,HF)简称心衰,是由各种原因所致心肌损伤最终导致心脏的心室泵血和(或)充盈能力下降的综合征,使静脉系统血液淤积,动脉系统血液灌注不足,从而引起心脏循环障碍症候群.HF具有患病率高,致死率高,医疗花费高等特点,呈现进行性发展、是严重危害着人类健康的一种疾病.然而,目前常规的HF治疗方法,无论是药物还是手术方式对患者获益仍十分有限.Entresto是新发现的一种具有脑啡肽酶/血管紧张素受体双重抑制效应的新型抗心衰药物,随着其上市应用与相关研究的报道,本文就其药效及药代学、临床研究及安全性等方面进行综述,为其合理应用于临床治疗HF提供更多研究依据.“,”Heart failure (HF),a myocardial injury syndrome with multiple etiologies,can result in reduction of ventricle pump function and/or filling ability with hypertension,coronary heart disease,and other cardiovascular pathogenesis.HF is a progressive disease,with high morbidity,a high fatality rate,and high associated medical costs.Unfortunately,at present,there are limited beneficial effects to current therupies.Entresto,which has dual effects on inhibition of both neprilysin and the rennin angiotensin aldosterone system,is a new type of drug utilized to treate HF.The present review aims to summarize pharmacodynamic/pharmacokinetics relationships,clinical efficacy,and the safety of Entresto.Finally,the review provides additional evidence for its clinical application.